tiprankstipranks
Trending News
More News >
ADC Therapeutics Ltd (ADCT)
NYSE:ADCT
US Market
Advertisement

ADC Therapeutics (ADCT) Stock Statistics & Valuation Metrics

Compare
375 Followers

Total Valuation

ADC Therapeutics has a market cap or net worth of $349.87M. The enterprise value is $491.04M.
Market Cap$349.87M
Enterprise Value$491.04M

Share Statistics

ADC Therapeutics has 112,499,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding112,499,400
Owned by Insiders42.97%
Owned by Institutions0.06%

Financial Efficiency

ADC Therapeutics’s return on equity (ROE) is 0.78 and return on invested capital (ROIC) is -53.85%.
Return on Equity (ROE)0.78
Return on Assets (ROA)-0.49
Return on Invested Capital (ROIC)-53.85%
Return on Capital Employed (ROCE)-0.54
Revenue Per Employee269.34K
Profits Per Employee-600.17K
Employee Count263
Asset Turnover0.22
Inventory Turnover0.32

Valuation Ratios

The current PE Ratio of ADC Therapeutics is ―. ADC Therapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value-0.95
Price to FCF
Price to Operating Cash Flow-2.47
PEG Ratio

Income Statement

In the last 12 months, ADC Therapeutics had revenue of 70.84M and earned -157.85M in profits. Earnings per share was -1.62.
Revenue70.84M
Gross Profit64.89M
Operating Income-130.65M
Pretax Income-156.14M
Net Income-157.85M
EBITDA-103.71M
Earnings Per Share (EPS)-1.62

Cash Flow

In the last 12 months, operating cash flow was -134.81M and capital expenditures -590.80K, giving a free cash flow of -135.40M billion.
Operating Cash Flow-134.81M
Free Cash Flow-135.40M
Free Cash Flow per Share-1.20

Dividends & Yields

ADC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta2.58
52-Week Price Change-2.45%
50-Day Moving Average3.00
200-Day Moving Average2.20
Relative Strength Index (RSI)57.66
Average Volume (3m)682.13K

Important Dates

ADC Therapeutics upcoming earnings date is Nov 11, 2025, Before Open (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 11, 2025
Ex-Dividend Date

Financial Position

ADC Therapeutics as a current ratio of 3.82, with Debt / Equity ratio of -140.50%
Current Ratio3.82
Quick Ratio3.59
Debt to Market Cap0.59
Net Debt to EBITDA1.23
Interest Coverage Ratio-2.60

Taxes

In the past 12 months, ADC Therapeutics has paid 166.00K in taxes.
Income Tax166.00K
Effective Tax Rate>-0.01

Enterprise Valuation

ADC Therapeutics EV to EBITDA ratio is -0.63, with an EV/FCF ratio of -0.53.
EV to Sales0.95
EV to EBITDA-0.63
EV to Free Cash Flow-0.53
EV to Operating Cash Flow-0.53

Balance Sheet

ADC Therapeutics has $194.70M in cash and marketable securities with $334.70M in debt, giving a net cash position of $140.00M billion.
Cash & Marketable Securities$194.70M
Total Debt$334.70M
Net Cash$140.00M
Net Cash Per Share$1.24
Tangible Book Value Per Share-$2.09

Margins

Gross margin is 90.97%, with operating margin of -188.59%, and net profit margin of -227.84%.
Gross Margin90.97%
Operating Margin-188.59%
Pretax Margin-225.37%
Net Profit Margin-227.84%
EBITDA Margin-149.70%
EBIT Margin-152.89%

Analyst Forecast

The average price target for ADC Therapeutics is $7.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$7.50
Price Target Upside135.85% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast15.73%
EPS Growth Forecast38.73%

Scores

Smart Score6
AI Score54
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis